Abstract

The carboxyl terminus of Hsp70-interacting protein (CHIP) acts as a ubiquitin E3 ligase and a link between the chaperones Hsp70/90 and the proteasome system, playing a vital role in maintaining protein homeostasis. CHIP regulates a number of proteins involved in a myriad of physiological and pathological processes, but the underlying mechanism of action via posttranslational modification has not been extensively explored. In this study, we investigated a novel modulatory mode of CHIP and its effect on CHIP enzymatic activity. ISG15, an ubiquitin-like modifier, is induced by type I interferon (IFN) stimulation and can be conjugated to target proteins (ISGylation). Here we demonstrated that CHIP may be a novel target of ISGylation in HEK293 cells stimulated with type I IFN. We also found that Lys143/144/145 and Lys287 residues in CHIP are important for and target residues of ISGylation. Moreover, ISGylation promotes the E3 ubiquitin ligase activity of CHIP, subsequently causing a decrease in levels of oncogenic c-Myc, one of its many ubiquitination targets, in A549 lung cancer cells and inhibiting A549 cell and tumor growth. In conclusion, the present study demonstrates that covalent ISG15 conjugation produces a novel CHIP regulatory mode that enhances the tumor-suppressive activity of CHIP, thereby contributing to the antitumor effect of type I IFN.

Highlights

  • Type I interferons (IFNs) constitute a family of cytokines that are widely used in the treatment of some types of cancer and viral disease

  • Based on the previous findings that carboxyl terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination and proteolysis of substrates are closely associated with type I IFN production and inflammatory signaling[28,29], we investigated the effect of ISG15 on CHIP and its E3 ligase activity

  • When A549 cells were stimulated with IFN-α to induce ISGylation, western blot analysis demonstrated that expression of ISG15 is strongly induced, as expected, and protein ISGylation is subsequently increased (Fig. 1a)

Read more

Summary

Introduction

Type I interferons (IFNs) constitute a family of cytokines that are widely used in the treatment of some types of cancer and viral disease. IFN-α has a therapeutic effect in >14 types of cancer, such as melanoma, renal carcinoma, and Kaposi’s sarcoma[1,2]. IFN-α indirectly affects cancer by activating innate immune responses and delays tumor cell growth by inhibiting tumor cell proliferation and angiogenesis. IFNα upregulates the expression of numerous IFN-stimulated genes (ISGs) that directly affect tumor cell growth, ISG15 is the first reported ubiquitin-like modifier and is highly inducible by type I IFNs4. ISG15 is conjugated to specific lysine residues of target proteins (ISGylation). ISGylation requires E1, E2, and E3 enzymes, all of which are induced by type I IFNs5,6.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call